Treating Protein C Deficiency
SLU ID 14-016 | Thrombin-Thrombomodulin chimera as a protein C activator
Intellectual Property Status
Seeking
Patented
Know-how based
Licensee
Development partner
Commercial partner
Investment
University spin out
Background
Protein C deficiency is a rare genetic disorder that increases the risk of developing abnormal blood clots. The condition can be mild to severe. Those with the condition have an increased risk for deep vein thrombosis and pulmonary embolism.
Overview
Researchers at Saint Louis University have identified thrombin-thrombomodulin fusion proteins, vectors, and host cells that act as protein C activators. They have also developed methods for preparing the thrombin-thrombomodulin fusion proteins.
Benefits
The potential benefits of this technology include:
Increasing the specificity of treatments
Minimizing production costs
Minimizing the risk of developing deep vein thrombosis
Minimizing the risk of developing a pulmonary embolism
Applications
The potential applications of this technology include:
treating protein C deficiency
Opportunity
Saint Louis University is seeking a partner to further develop and commercialize this technology.